BAT Reports Strong Business Growth in Next-Generation Products

Jun.08.2023
BAT Reports Strong Business Growth in Next-Generation Products
British American Tobacco reports strong growth in e-cigarettes and heated tobacco products, but warns of potential impact from business relocations from Russia and Belarus.

Recently, according to a report from news24, British American Tobacco (BAT) has released its half-year trading update and its stock price has remained stable. CEO Tadeu Marroco stated that the business revenue from electronic cigarettes and heated tobacco products has grown strongly, and once again confirmed that the company should be profitable by 2024.

 

The product portfolio of British American Tobacco (BAT) is well-balanced, featuring not only traditional cigarette brands such as Dunhill, Peter Stuyvesant, Rothmans, and Pall Mall, but also electronic and heated tobacco products, including Vuse, glo, and Velo.

 

The company still maintains a cash conversion rate of over 90% for operations, with the group expecting a mid-single digit increase in diluted earnings per share (calculated using a fixed exchange rate) and revenue growth of 3% to 5% for the full year. However, BAT has issued a warning that the projected growth may be affected due to the anticipated transfer of its Russian and Belarusian operations this year.

 

The company stated that their overall market share for cigarette sales has increased by 10 basis points in the last six months, despite disappointing performance in the American market.

 

The newly appointed CEO of BAT, Tadeu Marroco, has stated that the revenue growth of their e-cigarette and heated tobacco products is "strong" and has once again confirmed that the company should be profitable by 2024.

 

Our strategic goal is to gradually transform our product portfolio by actively encouraging adult smokers to switch to products with lower risks compared to smoking; this transformation will bring long-term value to multiple stakeholders.

 

However, BAT has also warned that its tobacco heating device brand, Glo, has seen a decline of over one percentage point in market share in key countries. Despite gaining market share in some European countries, it has faced intense competition from other products in the markets of Japan and Italy. According to market analysis, the main competitor for glo from British American Tobacco is IQOS from Philip Morris International.

 

The e-cigarette brand, Vuse, has seen a nearly three percentage point increase in market share, now holding a 39% share in the crucial e-cigarette market, and growth in the U.S. market.

 

In face of California's ban on the sale of most flavored tobacco products and e-cigarettes that took effect in December 2022, BAT has stated that the long-term impact of the flavor prohibition remains difficult to predict.

 

According to reports, mint-flavored products are continuing to be sold illegally due to lax law enforcement. We have also observed an increase in sales of flavored products in neighboring states.

 

Analysts believe that this may indicate a possibility of relaxation in the "flavor ban".

 

Currently, the disposable flavored electronic cigarette product, Vuse Go, is sold in 40 markets and is expanding sales in emerging markets such as Colombia and Peru. The initial results are "encouraging.

 

It is noteworthy that in the past year, the stock prices of BAT have dropped by 10%, which has left investors disappointed with the company's decision to suspend its new stock buyback plans.

 

Reference(s):

 

British American Tobacco maintains its profit outlook despite challenging conditions in the US cigarette market, despite suffering losses in its global operations.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
New York’s 75% Wholesale Tax on Nicotine Pouches Takes Effect Sept. 1, With Aug. 31 Inventory Subject to Floor Tax
New York’s 75% Wholesale Tax on Nicotine Pouches Takes Effect Sept. 1, With Aug. 31 Inventory Subject to Floor Tax
New York State will extend its tobacco products tax to “alternative nicotine products,” including tobacco-free nicotine pouches, from September 1, 2026, at a rate of 75% of the wholesale price. Distributors, wholesalers and retailers must also inventory products held as of 11:59 p.m. on August 31 and pay a floor tax. Vapor products are excluded from the new category and remain subject to New York's separate 20% supplemental sales tax on the retail price.
Aug.26
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
U.S. President Donald Trump has named Pastor Darrell Scott to serve as an adviser on tobacco health issues on the Centers for Disease Control and Prevention’s Advisory Committee to the Director. Trump said Scott would focus on the burden of tobacco-related disease and help examine ways to protect Americans from dangerous tobacco products while supporting solutions that reduce harm. Scott’s public career has largely centered on faith leadership, community advocacy and politics.
Sep.02
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11